Deirdre Dunne
@dunnedeirdre.bsky.social
Executive Publisher @ Elsevier
Working together with the European Society for Medical Oncology (ESMO)
Working together with the European Society for Medical Oncology (ESMO)
Today’s Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
October 19, 2025 at 11:26 AM
Today’s Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
The First Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
October 18, 2025 at 8:02 AM
The First Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
Reposted by Deirdre Dunne
Update from the #POSITIVE trial at #ESMO25 - 71-month follow-up showed no increase in recurrence among women who paused treatment to conceive, offering important reassurance for patients and clinicians 👏
🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer
🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer
October 17, 2025 at 12:48 PM
Update from the #POSITIVE trial at #ESMO25 - 71-month follow-up showed no increase in recurrence among women who paused treatment to conceive, offering important reassurance for patients and clinicians 👏
🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer
🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer
Reposted by Deirdre Dunne
Another fantastic @myesmo.bsky.social GI oncology podcast about #oligometastatic #gastric cancer is finally out!
Please take a moment to 🎧 and share it with your team:
soundcloud.com/esmo-podcast...
Please take a moment to 🎧 and share it with your team:
soundcloud.com/esmo-podcast...
Controversies in upper GI oncology: the definition and management of oligometastatic gastroesophageal tumours
In this Controversies in upper GI oncology podcast, Angelica Petrillo, gastrointestinal oncologist of Ospedale del Mare, Naples, Italy, presents a discussion between Professor Hanneke van Laarhoven,
soundcloud.com
July 1, 2025 at 3:30 PM
Another fantastic @myesmo.bsky.social GI oncology podcast about #oligometastatic #gastric cancer is finally out!
Please take a moment to 🎧 and share it with your team:
soundcloud.com/esmo-podcast...
Please take a moment to 🎧 and share it with your team:
soundcloud.com/esmo-podcast...
Reposted by Deirdre Dunne
ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care
@myesmo.bsky.social
oncodaily.com/societies/es...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO
@myesmo.bsky.social
oncodaily.com/societies/es...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO
ESMO 50th Anniversary: Half a Century of Evidence-Based Can
ESMO 50th Anniversary was celebrated on June 27, 2025, marking a historic milestone in the evolution of global cancer care. Over five decades,
oncodaily.com
July 3, 2025 at 10:01 PM
ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care
@myesmo.bsky.social
oncodaily.com/societies/es...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO
@myesmo.bsky.social
oncodaily.com/societies/es...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO
Reposted by Deirdre Dunne
Updates from the ESMO Gastrointestinal Cancers Congress 2025
@myesmo.bsky.social
oncodaily.com/insight/esmo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #GIOnc
@myesmo.bsky.social
oncodaily.com/insight/esmo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #GIOnc
Updates from the ESMO Gastrointestinal Cancers Congress 2025 - OncoDaily
Updates from the ESMO Gastrointestinal Cancers Congress 2025 / cancer, colorectal cancer, CRC, ESMO, ESMO Daily Reporter, ESMO Gastrointestinal Cancers, ESMO
oncodaily.com
July 3, 2025 at 10:08 PM
Updates from the ESMO Gastrointestinal Cancers Congress 2025
@myesmo.bsky.social
oncodaily.com/insight/esmo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #GIOnc
@myesmo.bsky.social
oncodaily.com/insight/esmo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #GIOnc
Reposted by Deirdre Dunne
🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻
Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.
Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.
April 12, 2025 at 7:14 AM
🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻
Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.
Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.
Reposted by Deirdre Dunne
New research in Annals of Oncology shows that a breath-based diagnostic tool—an “electronic nose”—is getting surprisingly close to clinical reality. #lungcancer
Sniffing Out Lung Cancer: Breath Analyzer Moves Closer to Clinical Use
So-called eNose achieves 80-90% performance level for lung cancer detection
www.medpagetoday.com
April 15, 2025 at 2:04 PM
New research in Annals of Oncology shows that a breath-based diagnostic tool—an “electronic nose”—is getting surprisingly close to clinical reality. #lungcancer
Reposted by Deirdre Dunne
📢 New in Annals of Oncology: Final survival results from the #PENELOPEB trial: Palbociclib vs placebo in high-risk HR+/HER2- breast cancer after neoadjuvant chemo.
Full paper: www.annalsofoncology.org/article/S092...
Full paper: www.annalsofoncology.org/article/S092...
April 23, 2025 at 9:43 AM
📢 New in Annals of Oncology: Final survival results from the #PENELOPEB trial: Palbociclib vs placebo in high-risk HR+/HER2- breast cancer after neoadjuvant chemo.
Full paper: www.annalsofoncology.org/article/S092...
Full paper: www.annalsofoncology.org/article/S092...
Reposted by Deirdre Dunne
📢 Delighted to share a new publication in Annals of Oncology.
PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social
PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social
May 31, 2025 at 8:53 AM
📢 Delighted to share a new publication in Annals of Oncology.
PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social
PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social
Reposted by Deirdre Dunne
Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study, published in Annals of Oncology.
👉 Read it before your patients: bit.ly/43NzBfO
👉 Read it before your patients: bit.ly/43NzBfO
June 4, 2025 at 7:10 AM
Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study, published in Annals of Oncology.
👉 Read it before your patients: bit.ly/43NzBfO
👉 Read it before your patients: bit.ly/43NzBfO
Reposted by Deirdre Dunne
Potential solid tumor indications for MRD continue to pile up, including new cervical cancer data presented at ASCO and simultaneously published in Annals of Oncology.
ASCO Data on Personalis Assay Suggests Role for ctDNA MRD Testing in Cervical Cancer
www.precisionmedicineonline.com
June 7, 2025 at 2:36 AM
Potential solid tumor indications for MRD continue to pile up, including new cervical cancer data presented at ASCO and simultaneously published in Annals of Oncology.
Reposted by Deirdre Dunne
👉 Asia Pacific’s oncology spotlight is on you. Submit your abstract for ESMO Asia 2025 by 12 August. Get published in Annals of Oncology and connect with top experts in Singapore, 5–7 December.
Your research. Your impact. #ESMOAsia25
🔗 buff.ly/ycEGK9a
Your research. Your impact. #ESMOAsia25
🔗 buff.ly/ycEGK9a
June 11, 2025 at 1:28 PM
👉 Asia Pacific’s oncology spotlight is on you. Submit your abstract for ESMO Asia 2025 by 12 August. Get published in Annals of Oncology and connect with top experts in Singapore, 5–7 December.
Your research. Your impact. #ESMOAsia25
🔗 buff.ly/ycEGK9a
Your research. Your impact. #ESMOAsia25
🔗 buff.ly/ycEGK9a
Reposted by Deirdre Dunne
Great to see our comprehensive study showing a strong correlation of PFS and OS after first-line treatment for Hodgkin Lymphoma now published in the current issue of Annals of Oncology www.sciencedirect.com/science/arti... with a nice Editorial by Drs. Yamauchi & Maruyama doi.org/10.1016/j.an...
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trial...
This study aimed to evaluate the correlation between progression-free (PFS) and overall survival (OS) after first-line treatment of classical Hodgkin …
www.sciencedirect.com
April 2, 2025 at 8:36 AM
Great to see our comprehensive study showing a strong correlation of PFS and OS after first-line treatment for Hodgkin Lymphoma now published in the current issue of Annals of Oncology www.sciencedirect.com/science/arti... with a nice Editorial by Drs. Yamauchi & Maruyama doi.org/10.1016/j.an...
An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers!
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
March 20, 2025 at 8:07 PM
An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers!
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
Reposted by Deirdre Dunne
Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹.
If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal:
🔗 esmoiotech.org
If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal:
🔗 esmoiotech.org
December 11, 2024 at 11:00 AM
Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹.
If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal:
🔗 esmoiotech.org
If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal:
🔗 esmoiotech.org
📢👏👏👏👏👏THANKS TO REFEREES 2024: The Editor-in-Chief and Associate Editors of Annals of Oncology would like to extend their sincere appreciation to all those who have worked as referees for the journal.
www.sciencedirect.com/science/arti... #ESMO
www.sciencedirect.com/science/arti... #ESMO
THANKS TO REFEREES 2024
www.sciencedirect.com
December 4, 2024 at 5:55 AM
📢👏👏👏👏👏THANKS TO REFEREES 2024: The Editor-in-Chief and Associate Editors of Annals of Oncology would like to extend their sincere appreciation to all those who have worked as referees for the journal.
www.sciencedirect.com/science/arti... #ESMO
www.sciencedirect.com/science/arti... #ESMO
New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial
www.sciencedirect.com/science/arti... #ESMO
www.sciencedirect.com/science/arti... #ESMO
December 4, 2024 at 5:52 AM
New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial
www.sciencedirect.com/science/arti... #ESMO
www.sciencedirect.com/science/arti... #ESMO
📖 #AnnalsOfOncology #DYK
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
December 4, 2024 at 5:48 AM
📖 #AnnalsOfOncology #DYK
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology
www.esmorarecancers.org/article/S305...
www.esmorarecancers.org/article/S305...
November 26, 2024 at 12:24 PM
I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology
www.esmorarecancers.org/article/S305...
www.esmorarecancers.org/article/S305...
📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO
🔗 ow.ly/9LCT50U8U9f
🔗 ow.ly/9LCT50U8U9f
November 25, 2024 at 9:09 AM
📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO
🔗 ow.ly/9LCT50U8U9f
🔗 ow.ly/9LCT50U8U9f
📖 @Annals of Oncology marks 35 years with Prof. David Kerr, Editor-in-Chief (2000-2009). He reflects on the journal’s growth, challenges, and offers advice for emerging researchers.
Read the full interview
🔗 ow.ly/Osug50UbMfe
Read the full interview
🔗 ow.ly/Osug50UbMfe
Annals of Oncology 35th Anniversary - Interview with Prof. David Kerr
Prof. Kerr discusses the challenges he faced, the journal’s evolution, and its growing impact on the field
ow.ly
November 24, 2024 at 7:34 PM
📖 @Annals of Oncology marks 35 years with Prof. David Kerr, Editor-in-Chief (2000-2009). He reflects on the journal’s growth, challenges, and offers advice for emerging researchers.
Read the full interview
🔗 ow.ly/Osug50UbMfe
Read the full interview
🔗 ow.ly/Osug50UbMfe
👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25
🔗 ow.ly/bxph50Ua6zJ
🔗 ow.ly/bxph50Ua6zJ
November 22, 2024 at 11:59 AM
👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25
🔗 ow.ly/bxph50Ua6zJ
🔗 ow.ly/bxph50Ua6zJ
📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO
🔗 ow.ly/uC6R50UbLJE
🔗 ow.ly/uC6R50UbLJE
November 22, 2024 at 11:52 AM
📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO
🔗 ow.ly/uC6R50UbLJE
🔗 ow.ly/uC6R50UbLJE
📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023?
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
November 21, 2024 at 10:27 AM
📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023?
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP